UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 312

Sortiert nach

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

The journal of clinical endocrinology and metabolism, 2012-09, Vol.97 (9), p.3319-3325

2012

Volltextzugriff (PDF)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Diabetes care, 2013-10, Vol.36 (10), p.3169-3176

2013

Volltextzugriff (PDF)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

Diabetes care, 2011-12, Vol.34 (12), p.2496-2501

2011

Volltextzugriff (PDF)

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

Diabetes (New York, N.Y.), 1996-01, Vol.45 (1), p.91

1996

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements

Journal of diabetes science and technology, 2022-03, Vol.16 (2), p.401-407

2022

Volltextzugriff (PDF)

Implementing a Just Culture: Perceptions of Nurse Managers of Required Knowledge, Skills and Attitudes

Nursing leadership (Toronto, Ont.), 2016-12, Vol.29 (4), p.35

2016

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

Current medical research and opinion, 2009-11, Vol.25 (11), p.2679-2687

2009

Volltextzugriff (PDF)

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Journal of diabetes, 2016-01, Vol.8 (1), p.166-169

2016

Volltextzugriff (PDF)

Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance

Diabetes (New York, N.Y.), 1994-02, Vol.43 (2), p.247

1994

Volltextzugriff (PDF)

Growth factors and angiogenesis

Cardiovascular research, 1993-07, Vol.27 (7), p.1155-1161

1993

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2012-12, Vol.14 (12), p.1114-1122

2012

Volltextzugriff (PDF)

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes; 1ä½¿è°peglisproè°è

Journal of diabetes, 2016-01, Vol.8 (1), p.166

2016

Volltextzugriff (PDF)

Reduction in short‐acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes: 1型糖尿病患者使用基础胰岛素peglispro与甘精胰岛素相比短效胰岛素的需求减少伴随血糖控制的改善

Journal of diabetes, 2016-01, Vol.8 (1), p.166-169

2016

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care 2011;34:2496–2501

Diabetes care, 2014-08, Vol.37 (8), p.2414-2414

2014

Volltextzugriff (PDF)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Volltextzugriff (PDF)

Comorbid Illness Is Associated with Survival and Length of Hospital Stay in Patients with Chronic Disability: A Prospective Comparison of Three Comorbidity Indices

Medical care, 1996-11, Vol.34 (11), p.1093-1101

1996

Volltextzugriff (PDF)

Effects of epinephrine on insulin secretion and action in humans. Interaction with aging

Diabetes (New York, N.Y.), 1993-02, Vol.42 (2), p.307

1993

Volltextzugriff (PDF)

An examination of the relationship between organizational factors that influence implementation of an injury prevention program and degree and type of innovation re -invention

Morrow, Linda A

2009

Volltextzugriff (PDF)

Building on student diversity: Profiles and activities

SAGE Publications (CA), 2007

2007

Volltextzugriff (PDF)

Early Phase Metabolic Research with Reference to Special Populations

Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease, p.517-538

Volltextzugriff (PDF)

Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance

The journal of clinical endocrinology and metabolism, 1994-07, Vol.79 (1), p.205-210

1994

Volltextzugriff (PDF)

Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus

Diabetes research and clinical practice, 1995-08, Vol.28 (AOU), p.S185-S194

1995

Volltextzugriff (PDF)

Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans

The journal of clinical endocrinology and metabolism, 1987-09, Vol.65 (3), p.508-511

1987

Volltextzugriff (PDF)

Risk Assessment for Pressure Ulcers: An Adaptation of the National Pressure Ulcer Advisory Panel Risk Factors to Spinal Cord Injured Patients

The Journal of the American Paraplegia Society, 1993-07, Vol.16 (3), p.169-177

1993

Volltextzugriff (PDF)

1 – 25 von 312

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(266)
Mit Volltextzugriff
(245)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Humans
(142)
Life Sciences & Biomedicine
(142)
Female
(101)
Male
(81)
Adult
(68)
Middle Aged
(61)
Aged
(52)
Biological And Medical Sciences
(50)
Medical Sciences
(46)
Insulin
(27)
Endocrinology & Metabolism
(26)
Diabetes
(24)
Aged, 80 And Over
(23)
Prospective Studies
(23)
Treatment Outcome
(20)
Adolescent
(19)
Diabetes Mellitus, Type 2 - Drug Therapy
(18)
Double-Blind Method
(18)
Glucose
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements

Implementing a Just Culture: Perceptions of Nurse Managers of Required Knowledge, Skills and Attitudes

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance

Growth factors and angiogenesis

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes; 1ä½¿è°peglisproè°è

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care 2011;34:2496–2501

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Comorbid Illness Is Associated with Survival and Length of Hospital Stay in Patients with Chronic Disability: A Prospective Comparison of Three Comorbidity Indices

Effects of epinephrine on insulin secretion and action in humans. Interaction with aging

An examination of the relationship between organizational factors that influence implementation of an injury prevention program and degree and type of innovation re -invention

Building on student diversity: Profiles and activities

Early Phase Metabolic Research with Reference to Special Populations

Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance

Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus

Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans

Risk Assessment for Pressure Ulcers: An Adaptation of the National Pressure Ulcer Advisory Panel Risk Factors to Spinal Cord Injured Patients

Suchergebnisse filtern